Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis
Campos Pacheco, Jesús E. ; Yalovenko, Tetiana ; Riaz, Azra ; Kotov, Nikolay ; Davids, Camilla LU ; Persson, Alva ; Falkman, Peter ; Feiler, Adam ; Godaly, Gabriela LU
and Johnson, C. Magnus
, et al.
(2024)
In Journal of Controlled Release
369.
p.231-250
- Abstract
Inhalation therapy treating severe infectious disease is among the more complex and emerging topics in controlled drug release. Micron-sized carriers are needed to deposit drugs into the lower airways, while nano-sized carriers are of preference for cell targeting. Here, we present a novel and versatile strategy using micron-sized spherical particles with an excellent aerodynamic profile that dissolve in the lung fluid to ultimately generate nanoparticles enabling to enhance both extra- and intra-cellular drug delivery (i.e., dual micro-nano inhalation strategy). The spherical particles are synthesised through the condensation of nano-sized amorphous silicon dioxide resulting in high surface area, disordered mesoporous silica particles... (More)
Inhalation therapy treating severe infectious disease is among the more complex and emerging topics in controlled drug release. Micron-sized carriers are needed to deposit drugs into the lower airways, while nano-sized carriers are of preference for cell targeting. Here, we present a novel and versatile strategy using micron-sized spherical particles with an excellent aerodynamic profile that dissolve in the lung fluid to ultimately generate nanoparticles enabling to enhance both extra- and intra-cellular drug delivery (i.e., dual micro-nano inhalation strategy). The spherical particles are synthesised through the condensation of nano-sized amorphous silicon dioxide resulting in high surface area, disordered mesoporous silica particles (MSPs) with monodispersed size of 2.43 μm. Clofazimine (CLZ), a drug shown to be effective against multidrug-resistant tuberculosis, was encapsulated in the MSPs obtaining a dry powder formulation with high respirable fraction (F.P.F. <5 μm of 50%) without the need of additional excipients. DSC, XRPD, and Nitrogen adsorption-desorption indicate that the drug was fully amorphous when confined in the nano-sized pores (9–10 nm) of the MSPs (shelf-life of 20 months at 4 °C). Once deposited in the lung, the CLZ-MSPs exhibited a dual action. Firstly, the nanoconfinement within the MSPs enabled a drastic dissolution enhancement of CLZ in simulated lung fluid (i.e., 16-fold higher than the free drug), increasing mycobacterial killing than CLZ alone (p = 0.0262) and reaching concentrations above the minimum bactericidal concentration (MBC) against biofilms of M. tuberculosis (i.e., targeting extracellular bacteria). The released CLZ permeated but was highly retained in a Calu-3 respiratory epithelium model, suggesting a high local drug concentration within the lung tissue minimizing risk for systemic side effects. Secondly, the micron-sized drug carriers spontaneously dissolve in simulated lung fluid into nano-sized drug carriers (shown by Nano-FTIR), delivering high CLZ cargo inside macrophages and drastically decreasing the mycobacterial burden inside macrophages (i.e., targeting intracellular bacteria). Safety studies showed neither measurable toxicity on macrophages nor Calu-3 cells, nor impaired epithelial integrity. The dissolved MSPs also did not show haemolytic effect on human erythrocytes. In a nutshell, this study presents a low-cost, stable and non-invasive dried powder formulation based on a dual micro-nano carrier to efficiently deliver drug to the lungs overcoming technological and practical challenges for global healthcare.
(Less)
- author
- Campos Pacheco, Jesús E.
; Yalovenko, Tetiana
; Riaz, Azra
; Kotov, Nikolay
; Davids, Camilla
LU
; Persson, Alva
; Falkman, Peter
; Feiler, Adam
; Godaly, Gabriela
LU
and Johnson, C. Magnus
, et al. (More)
- Campos Pacheco, Jesús E.
; Yalovenko, Tetiana
; Riaz, Azra
; Kotov, Nikolay
; Davids, Camilla
LU
; Persson, Alva
; Falkman, Peter
; Feiler, Adam
; Godaly, Gabriela
LU
; Johnson, C. Magnus
; Ekström, Mikael
; Pilkington, Georgia A.
and Valetti, Sabrina
(Less)
- organization
- publishing date
- 2024-05
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Clofazimine, Disordered mesoporous silica particles, Dissolution enhancement, Dried powder formulation, Dual micro-nano carrier, Lung drug delivery, Soluble carrier
- in
- Journal of Controlled Release
- volume
- 369
- pages
- 20 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85189001903
- pmid:38479444
- ISSN
- 0168-3659
- DOI
- 10.1016/j.jconrel.2024.03.013
- language
- English
- LU publication?
- yes
- id
- eba8b971-7bb4-4c4a-b487-0247642240c5
- date added to LUP
- 2024-04-12 14:00:32
- date last changed
- 2024-12-07 16:05:22
@article{eba8b971-7bb4-4c4a-b487-0247642240c5,
abstract = {{<p>Inhalation therapy treating severe infectious disease is among the more complex and emerging topics in controlled drug release. Micron-sized carriers are needed to deposit drugs into the lower airways, while nano-sized carriers are of preference for cell targeting. Here, we present a novel and versatile strategy using micron-sized spherical particles with an excellent aerodynamic profile that dissolve in the lung fluid to ultimately generate nanoparticles enabling to enhance both extra- and intra-cellular drug delivery (i.e., dual micro-nano inhalation strategy). The spherical particles are synthesised through the condensation of nano-sized amorphous silicon dioxide resulting in high surface area, disordered mesoporous silica particles (MSPs) with monodispersed size of 2.43 μm. Clofazimine (CLZ), a drug shown to be effective against multidrug-resistant tuberculosis, was encapsulated in the MSPs obtaining a dry powder formulation with high respirable fraction (F.P.F. <5 μm of 50%) without the need of additional excipients. DSC, XRPD, and Nitrogen adsorption-desorption indicate that the drug was fully amorphous when confined in the nano-sized pores (9–10 nm) of the MSPs (shelf-life of 20 months at 4 °C). Once deposited in the lung, the CLZ-MSPs exhibited a dual action. Firstly, the nanoconfinement within the MSPs enabled a drastic dissolution enhancement of CLZ in simulated lung fluid (i.e., 16-fold higher than the free drug), increasing mycobacterial killing than CLZ alone (p = 0.0262) and reaching concentrations above the minimum bactericidal concentration (MBC) against biofilms of M. tuberculosis (i.e., targeting extracellular bacteria). The released CLZ permeated but was highly retained in a Calu-3 respiratory epithelium model, suggesting a high local drug concentration within the lung tissue minimizing risk for systemic side effects. Secondly, the micron-sized drug carriers spontaneously dissolve in simulated lung fluid into nano-sized drug carriers (shown by Nano-FTIR), delivering high CLZ cargo inside macrophages and drastically decreasing the mycobacterial burden inside macrophages (i.e., targeting intracellular bacteria). Safety studies showed neither measurable toxicity on macrophages nor Calu-3 cells, nor impaired epithelial integrity. The dissolved MSPs also did not show haemolytic effect on human erythrocytes. In a nutshell, this study presents a low-cost, stable and non-invasive dried powder formulation based on a dual micro-nano carrier to efficiently deliver drug to the lungs overcoming technological and practical challenges for global healthcare.</p>}},
author = {{Campos Pacheco, Jesús E. and Yalovenko, Tetiana and Riaz, Azra and Kotov, Nikolay and Davids, Camilla and Persson, Alva and Falkman, Peter and Feiler, Adam and Godaly, Gabriela and Johnson, C. Magnus and Ekström, Mikael and Pilkington, Georgia A. and Valetti, Sabrina}},
issn = {{0168-3659}},
keywords = {{Clofazimine; Disordered mesoporous silica particles; Dissolution enhancement; Dried powder formulation; Dual micro-nano carrier; Lung drug delivery; Soluble carrier}},
language = {{eng}},
pages = {{231--250}},
publisher = {{Elsevier}},
series = {{Journal of Controlled Release}},
title = {{Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis}},
url = {{http://dx.doi.org/10.1016/j.jconrel.2024.03.013}},
doi = {{10.1016/j.jconrel.2024.03.013}},
volume = {{369}},
year = {{2024}},
}